AMAL Therapeutics

Executive Summary

AMAL Therapeutics is a Swiss biotech company pioneering the development of therapeutic vaccines for oncology and infectious diseases through its proprietary KISIMA® platform. Founded in 2012 and headquartered in Geneva, the company leverages a unique multi-antigen, multi-epitope approach designed to elicit potent and specific T-cell responses, overcoming immune tolerance and addressing high-unmet medical needs. The KISIMA technology combines a cell-penetrating peptide, a toll-like receptor agonist, and multiple antigens in a single construct, enabling robust and durable immunity. While the company has not yet advanced candidates to late-stage clinical trials, its platform has generated promising preclinical data and potential for application across multiple indications, including HPV-associated cancers and malaria. As a private entity, AMAL has attracted interest from strategic partners and investors, positioning itself for potential growth through clinical validation and partnerships.

Upcoming Catalysts (preview)

• Q1 2027Initiation of Phase 1/2 clinical trial for lead oncology candidate60% success
• Q3 2026Presentation of preclinical proof-of-concept data at major conference (e.g., SITC or ASCO)80% success
• Q4 2026Announcement of strategic partnership or licensing deal for KISIMA platform50% success